Monjuvi, Revlimid Combo May Help Prevent Diffuse Large B-Cell Lymphoma Relapse

Adding Monjuvi (tafasitamab) and Revlimid (lenalidomide) to the standard treatment regimen R-CHOP, which combines Rituxan (rituximab) with four chemotherapy drugs and is commonly used as a first treatment for diffuse large B-cell lymphoma (DLBCL), helped patients with high-risk DLBCL stay in remission longer and reduced the risk of disease progression or death by 25%, according to findings from the phase 3 frontMIND trial presented at the 2026 ASCO Annual Meeting.

For patients, the findings are important because approximately 40% of people with DLBCL are not cured with standard first-line R-CHOP treatment and may see their cancer return after treatment.

"The important finding is improvement of progression-free survival, which leads to less relapses and less subsequent therapies," said Dr. Georg Lenz, professor and chair of the Department of Medicine A for Hematology, Oncology and Pneumology at University Hospital Münster in Germany, in an interview with CURE. "That is of major importance to our patients."

How Did Monjuvi and Revlimid Affect Patient Outcomes?

The international frontMIND study enrolled 899 patients with newly diagnosed high-risk DLBCL or high-grade B-cell lymphoma. Patients were randomly assigned to receive either Monjuvi plus Revlimid and R-CHOP or R-CHOP alone.

Researchers wanted to determine whether adding Monjuvi and Revlimid to frontline treatment could help patients remain free from disease progression for a longer period of time.

After a median follow-up of nearly three years, the combination met the study's primary goal.

Two years after starting treatment, 71.1% of patients who received Monjuvi, Revlimid and R-CHOP had not experienced disease progression or death compared with 62.9% of patients who received R-CHOP alone.

At three years, those rates were 67.3% and 60.7%, respectively.

Researchers also reported improvements in event-free survival, a measure that includes disease progression, starting a new treatment or death.

"Overall survival is numerically higher in patients receiving the novel combination," Lenz said. However, he noted that the overall survival data remain immature and longer follow-up is needed.

Why Does Progression-Free Survival Matter?

While hearing that a treatment improves progression-free survival may sound technical, it can have meaningful implications for patients.

Progression-free survival measures how long patients live without their cancer growing, spreading or returning. Improvements in this measure often mean fewer relapses and a longer period before additional treatment may be needed.

For patients with high-risk DLBCL, avoiding relapse is especially important because treatment options become more challenging once the disease returns.

"The important finding is improvement of progression-free survival, which leads to less relapses and less subsequent therapies," Lenz said.

Did More Patients Achieve Complete Remission?

One interesting finding was that the percentage of patients whose cancer completely disappeared after treatment was nearly identical between the two groups.

At the end of treatment, 65.2% of patients in both study arms achieved a complete response.

Overall response rates were slightly higher among patients who received Monjuvi, Revlimid and R-CHOP, but the biggest difference appeared to be how long patients remained free from disease progression after treatment.

"Interestingly, the rate of complete responders was the same," Lenz said. "But the number of patients achieving a partial remission was higher."

What Side Effects Were Reported?

The addition of Monjuvi and Revlimid resulted in more side effects than R-CHOP alone.

Serious side effects occurred more frequently in the Monjuvi-containing treatment arm, particularly infections and blood-related side effects. Researchers reported that 86.7% of patients receiving Monjuvi, Revlimid and R-CHOP experienced grade 3 or higher side effects compared with 76.1% of patients who received R-CHOP alone.

According to Lenz, doctors should pay close attention to infection prevention and supportive care measures when using this regimen.

"Tafasitamab, lenalidomide and R-CHOP induces more toxicities, more infections," he said.

Lenz said supportive care measures may include growth factor support and preventive medications such as cotrimoxazole or acyclovir for patients at increased risk of infection. He also noted that blood-related side effects were more common with the regimen, likely due to Revlimid, and should be monitored closely.

Despite the higher rate of side effects, investigators reported that the safety profile was generally manageable and consistent with what would be expected from the medications used in the regimen.

What Could These Findings Mean for Patients?

The frontMIND trial suggests that adding Monjuvi and Revlimid to R-CHOP may help reduce the chances that high-risk DLBCL will return after initial treatment.

Because relapse often leads to additional therapies, hospital visits and greater treatment burden, a longer period without disease progression may offer meaningful benefits for patients and their families.

Investigators concluded that Monjuvi, Revlimid and R-CHOP could potentially become a new first-line treatment option for patients with high-risk DLBCL and high-grade B-cell lymphoma.

Although longer follow-up is needed to determine whether the treatment improves overall survival, researchers say the reduction in relapses seen so far represents an important step forward for patients facing high-risk disease.

References

1. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP in patients with newly diagnosed high-risk diffuse large B-cell lymphoma or high-grade B-cell lymphoma: Primary analysis of the phase 3 frontMIND study. George Lenz , et al. Presented at the 2026 ASCO Annual Meeting.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.